X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare GSK Pharma with Aurobindo Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GSK PHARMA vs AUROBINDO PHARMA - Comparison Results

GSK PHARMA    Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GSK PHARMA AUROBINDO PHARMA GSK PHARMA/
AUROBINDO PHARMA
 
P/E (TTM) x 63.8 14.3 445.6% View Chart
P/BV x 10.3 3.7 278.8% View Chart
Dividend Yield % 1.2 0.4 290.9%  

Financials

 GSK PHARMA   AUROBINDO PHARMA
EQUITY SHARE DATA
    GSK PHARMA
Mar-17
AUROBINDO PHARMA
Mar-17
GSK PHARMA/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs3,838895 428.8%   
Low Rs2,637622 424.0%   
Sales per share (Unadj.) Rs354.2254.6 139.1%  
Earnings per share (Unadj.) Rs39.839.3 101.2%  
Cash flow per share (Unadj.) Rs42.946.6 92.0%  
Dividends per share (Unadj.) Rs30.002.50 1,200.0%  
Dividend yield (eoy) %0.90.3 281.1%  
Book value per share (Unadj.) Rs236.9160.0 148.1%  
Shares outstanding (eoy) m84.70585.88 14.5%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x9.13.0 306.8%   
Avg P/E ratio x81.419.3 421.6%  
P/CF ratio (eoy) x75.516.3 463.7%  
Price / Book Value ratio x13.74.7 288.2%  
Dividend payout %75.46.4 1,185.3%   
Avg Mkt Cap Rs m274,216444,390 61.7%   
No. of employees `0004.714.0 33.6%   
Total wages/salary Rs m4,83017,678 27.3%   
Avg. sales/employee Rs Th6,387.010,667.8 59.9%   
Avg. wages/employee Rs Th1,028.31,264.3 81.3%   
Avg. net profit/employee Rs Th717.11,645.8 43.6%   
INCOME DATA
Net Sales Rs m30,000149,157 20.1%  
Other income Rs m7281,159 62.8%   
Total revenues Rs m30,728150,316 20.4%   
Gross profit Rs m4,19034,343 12.2%  
Depreciation Rs m2634,276 6.2%   
Interest Rs m0667 0.0%   
Profit before tax Rs m4,65530,558 15.2%   
Minority Interest Rs m050 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m4570-   
Tax Rs m1,7447,597 23.0%   
Profit after tax Rs m3,36823,012 14.6%  
Gross profit margin %14.023.0 60.7%  
Effective tax rate %37.524.9 150.7%   
Net profit margin %11.215.4 72.8%  
BALANCE SHEET DATA
Current assets Rs m16,74292,062 18.2%   
Current liabilities Rs m7,20266,223 10.9%   
Net working cap to sales %31.817.3 183.6%  
Current ratio x2.31.4 167.2%  
Inventory Days Days52106 48.9%  
Debtors Days Days2168 30.7%  
Net fixed assets Rs m8,63562,919 13.7%   
Share capital Rs m847586 144.6%   
"Free" reserves Rs m19,22293,133 20.6%   
Net worth Rs m20,06993,719 21.4%   
Long term debt Rs m101,814 0.6%   
Total assets Rs m30,038162,494 18.5%  
Interest coverage xNM46.8-  
Debt to equity ratio x00 2.6%  
Sales to assets ratio x1.00.9 108.8%   
Return on assets %11.214.6 76.9%  
Return on equity %16.824.6 68.3%  
Return on capital %25.532.7 77.8%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m52875,838 0.7%   
Fx outflow Rs m7,19330,224 23.8%   
Net fx Rs m-6,66545,613 -14.6%   
CASH FLOW
From Operations Rs m2,36032,786 7.2%  
From Investments Rs m3,008-17,870 -16.8%  
From Financial Activity Rs m-5,108-19,153 26.7%  
Net Cashflow Rs m260-4,239 -6.1%  

Share Holding

Indian Promoters % 0.0 54.1 -  
Foreign collaborators % 50.7 0.0 -  
Indian inst/Mut Fund % 10.2 8.0 128.3%  
FIIs % 23.8 27.7 85.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 15.4 10.2 151.0%  
Shareholders   102,036 69,601 146.6%  
Pledged promoter(s) holding % 0.0 8.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GSK PHARMA With:   JUBILANT LIFE SCIENCES  DR. DATSONS LABS  ELDER PHARMA  NOVARTIS  PANACEA BIOTECH  

Compare GSK PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Rebound After Sharp Weekly Drop(RoundUp)

Global financial markets rallied this week and brushed aside a rise in global borrowing costs while the dollar hit its lowest level since 2014.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

As the Market Corrects... It's Time to Buy More(Smart Contrarian)

Feb 5, 2018

The recent sell off in the stock market offers buying opportunity in some quality small caps.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

What Should Mutual Fund Investors Do After LTCG Tax Norms(Outside View)

Feb 6, 2018

PersonalFN explain what investors should after LTCG tax norms.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GSK PHARMA SHARE PRICE


Feb 16, 2018 (Close)

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE GSK PHARMA WITH

MARKET STATS